Cerus (CERS) Expected to Announce Earnings on Thursday

Cerus (NASDAQ:CERS) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $47.44 million for the quarter.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Down 0.7 %

Shares of NASDAQ:CERS opened at $1.34 on Tuesday. The company has a market capitalization of $256.15 million, a PE ratio of -12.18 and a beta of 1.70. Cerus has a 1 year low of $1.12 and a 1 year high of $2.54. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The business has a fifty day moving average price of $1.44 and a two-hundred day moving average price of $1.64.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price objective on shares of Cerus in a research report on Friday, February 21st.

Insiders Place Their Bets

In other Cerus news, insider Richard J. Benjamin sold 18,949 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $27,476.05. Following the completion of the transaction, the insider now owns 715,850 shares in the company, valued at $1,037,982.50. This trade represents a 2.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Vivek K. Jayaraman sold 29,985 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $43,478.25. Following the completion of the sale, the chief operating officer now directly owns 1,477,330 shares in the company, valued at approximately $2,142,128.50. This trade represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 441,150 shares of company stock valued at $665,210 over the last ninety days. 3.40% of the stock is currently owned by insiders.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.